The viability and tolerability of this drug were confirmed during the PIONEER and SUSTAIN clinical trial programs. Like another similar short-lasting medication developed by Lotte Bjerre Knudsen, this drug possesses a spacer that links a lysine residue to a C18 fatty di-acid. A position 2 substitution from alanine to 2-amino⋅iso⋅butyric acid prevents this drug from being degraded by dipeptidyl peptidase-4. This drug, which is an (*) incretin mimetic and is sold under the name Rybelsus (10[1])by Novo Nordisk, reduces blood sugar levels in adults with type 2 diabetes. (10[2])In 2023, (-5[1])this drug accounted for over 88% of all GLP-1s being prescribed. (10[1])For 10 points, semaglutide is the generic name of what drug that has recently seen widespread use as a weight-loss medication? ■END■